Tandem Diabetes Care (TNDM) Net Cash Flow (2013 - 2026)

Tandem Diabetes Care has reported Net Cash Flow for 14 years, with the latest figure at $89.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 751.43% year-over-year to $89.8 million; the trailing twelve-month figure through Mar 2026 stood at $123.3 million (up 2470.0% YoY), and the FY2025 full-year result was $19.8 million, up 117.21% from the prior year.
• Net Cash Flow for Q1 2026 stood at $89.8 million, up from -$2.6 million in the prior quarter.
• The five-year high for Net Cash Flow was $89.8 million in Q1 2026, with the low at -$50.4 million in Q3 2023.
• Historically, Net Cash Flow has averaged $6.2 million across 5 years, with a median of $3.3 million in 2023.
• The largest YoY upside for Net Cash Flow was 1051.86% in 2025 against a maximum downside of 2680.52% in 2025.
• Tandem Diabetes Care's Net Cash Flow stood at $47.7 million in 2022, then slumped by 144.41% to -$21.2 million in 2023, then soared by 185.11% to $18.0 million in 2024, then plunged by 114.33% to -$2.6 million in 2025, then soared by 3575.3% to $89.8 million in 2026.
• The last three Net Cash Flow figures came in at $89.8 million (Q1 2026), -$2.6 million (Q4 2025), and $27.2 million (Q3 2025), per Business Quant data.